2024

Grifols ranked number one biotech company in Dow Jones Sustainability Indices December 16, 2024
Grifols concludes balance sheet improvement process with private placement of Senior Secured Notes and Revolving Credit Facility extension December 11, 2024
Grifols’ Board of Directors Announces Termination of Acquisition Discussions with Brookfield November 27, 2024
Grifols Delivers Strong Third-Quarter Performance Led by Biopharma 12.1% Growth November 7, 2024
Grifols awarded Gold Medal by EcoVadis for Sustainability Excellence November 5, 2024
Thomas Glanzmann becomes non-executive Chairman September 23, 2024
Grifols Accelerates Performance in Q2 and Reaffirms Full Year Guidance July 30, 2024
Grifols and Andorran government agree not to proceed with immunology research center July 25, 2024
Grifols appoints Rahul Srinivasan as new Chief Financial Officer July 4, 2024
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years July 1, 2024
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group June 18, 2024
Grifols shareholders approve all agenda items at 2024 Annual General Meeting June 14, 2024
Grifols succesfully closes the issuance of additional EUR 300 million secured notes June 4, 2024
Grifols on track to meet full-year guidance and reduce debt May 14, 2024
Grifols on track to close its strategic alliance with Haier in first half 2024 May 6, 2024
Grifols successfully completes its EUR 1 billion private placement of senior secured notes April 30, 2024
Grifols announces signing of private offering of EUR 1 billion senior secured notes due 2030 April 23, 2024
Nacho Abia begins tenure as new Grifols CEO April 2, 2024
Grifols shares CNMV statement March 25, 2024
Grifols closes a record year and accelerates profitable growth for 2024 February 29, 2024
Grifols announces changes in governance to separate management from ownership as part of planned strategy February 5, 2024
Grifols’ Credit Rating Affirmed by S&P Global; Outlook Stable January 19, 2024

2023

Grifols reaches strategic alliance with Haier Group and raises approximately USD 1.8 billion December 29, 2023
Victor Grifols Roura announces retirement from the Board of Directors; Albert Grifols Coma-Cros appointed as new Board Member December 19, 2023
Grifols renews its inclusion in the Dow Jones Sustainability Indices as one of the world s most sustainable companies December 11, 2023
Grifols accelerates EBITDA margin expansion to 25.1% and further improves its operating performance November 2, 2023
Grifols delivers 15% revenue growth, accelerates margin expansion in Q2 and raises guidance for FY23 July 27, 2023
Grifols delivers strong first quarter financials with 23% revenue growth and an Adjusted EBITDA margin above guidance of 21% May 9, 2023
Grifols realigns management structure to accelerate company performance and simplify its corporate governance May 8, 2023
Grifols delivers strong 2022 performance and is positioned for sustainable future growth February 28, 2023
Thomas Glanzmann new Grifols Executive Chairman, after Steven F. Mayer resignation February 21, 2023
Grifols announces comprehensive operational improvement plan including EUR 400 million annualized cost savings initiative February 15, 2023
Grifols included in Bloomberg Gender-Equality Index for the third consecutive year for its leadership in equality, diversity and inclusion January 31, 2023

2022

Grifols recognized as one of the world’s most sustainable companies by Dow Jones Sustainability Index for third consecutive year December 12, 2022
Grifols’ Biopharma delivers robust 34% operational growth in Q3, driving revenues to EUR 4,351m in the first nine months of 2022 November 8, 2022
Grifols invites to listen to webcast of November 8 Conference Call with Analysts November 4, 2022
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson October 3, 2022
Board of Directors communication in the context of considerable geopolitical uncertainty and market volatility September 26, 2022
Grifols’ credit rating reaffirmed by Moody’s and Fitch based on strong fundamentals and improving performance September 23, 2022
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada September 7, 2022
Grifols’ business momentum delivers EUR 2,810 million in revenues and EUR 618 million in EBITDA as plasma collections accelerate July 28, 2022
Grifols highlights the acceleration of its operating performance and reiterates its strong commitment to debt reduction June 16, 2022
Grifols highlights an increase in plasma and underscores innovation and sustainability as key growth pillars in its AGM June 10, 2022
Business Update 1Q 2022: Grifols accelerating plasma recovery while enhancing performance May 6, 2022
Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation April 25, 2022
Grifols demonstrates resilient performance despite a challenging backdrop while recovery in plasma collection gains momentum February 28, 2022
Grifols signs global collaboration agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis February 24, 2022
Grifols maintains its standing in the Bloomberg Gender-Equality Index for its commitment to equality January 26, 2022
Grifols achieves a high level of acceptance of its PTO to Biotest and advances on its strategic transaction January 26, 2022
Grifols announces the expiration of the Asset sale Offer January 11, 2022

2021

Grifols earns approval for the voluntary public tender offer of Biotest and advances its strategy to increase the availability of plasma-derived medicines October 26, 2021
Grifols increases access to plasma-derived therapies as part of its commitment to donors and patients October 13, 2021
Grifols divests its hemostasis technology business for USD 25 million October 6, 2021
Grifols closes its EUR 2 billion bond issuance to finance its investment in Biotest October 5, 2021
Grifols earns its first Fitch corporate rating with a BB- and stable outlook September 27, 2021
Grifols announces its investment in Biotest September 17, 2021
Grifols advances on its strategic investment from GIC with 90% of consents from its notes holders and lenders August 16, 2021
Grifols signs an agreement with ImmunoTek to open 21 plasma centers and further advances on its expansion plan July 30, 2021
The Bioscience Division grows 5.1% in the second quarter and raises first-half revenues to EUR 2,537 million July 29, 2021
Grifols endorses its commitment to a responsible business model and support of the 2030 Agenda for Sustainable Development by formally joining the United Nations Global Compact July 20, 2021
Grifols announces a strategic investment from GIC of USD 1 billion June 30, 2021
Grifols reaffirms its commitment to sustainability and innovation in its AGM and celebrates its 15th anniversary of being listed May 21, 2021
Grifols maintains its revenues and operational levels while enhancing its innovation strategy and securing its plasma supply May 4, 2021
Grifols advances in the execution of its expansion plan with the acquisition of 7 plasma centers in the U.S. April 7, 2021
Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19 April 2, 2021
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins March 9, 2021
Grifols publishes its 2020 Integrated Annual Report as part of its commitment to sustainability March 4, 2021
Grifols acquires 25 U.S.-based plasma centers from BPL ensuring one million additional liters for fractionation March 1, 2021
Grifols increases its revenues to 5,340 M€ and continues to demonstrate its resilience and commitment to sustainable growth February 26, 2021
Grifols is included in the Bloomberg Gender-Equality Index for its commitment to gender equality January 27, 2021

2020

Grifols creates a Sustainability Committee to strengthen its long-term sustainable growth model December 16, 2020
Grifols is included on Euronext Vigeo indices and recognized once again as one of the world's most sustainable companies December 9, 2020
Strategic alliance between Grifols and the Egyptian government to boost plasma-derived medicines self-sufficiency in the Middle East and Africa November 24, 2020
The Dow Jones Sustainability Index recognizes Grifols as one of the world’s most sustainable companies November 16, 2020
Grifols consolidates its Hospital Division as a reference in innovative solutions with the acquisition of the 49% stake in MedKeeper November 9, 2020
Grifols continues delivering solid revenue and earnings growth driven by the Bioscience and Diagnostic Divisions November 5, 2020
Grifols underlines the importance of plasma in its Annual General Shareholders’ Meeting October 9, 2020
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S. October 1, 2020
Grifols more committed than ever to its values and long-term vision six months into the pandemic September 14, 2020
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome September 7, 2020
Grifols revenues grow 10.5% to EUR 2,677 million driven by the Bioscience Division July 30, 2020
Grifols delivers first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials July 28, 2020
Results of Grifols’ AMBAR clinical trial published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association July 27, 2020
Grifols acquires 10% stake in Bloodbuy, cloud-based marketplace for blood products July 23, 2020
Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million July 20, 2020
Grifols starts commercializing TAVLESSE® in Europe, diversifying its medicines portfolio July 9, 2020
Grifols starts production of its hyperimmune immunoglobulin as a potential passive immune therapy against COVID-19 June 11, 2020
Grifols reinforces its liquidity position to EUR 1,700 million May 7, 2020
Grifols maintains its operational levels and continues to reinforce its commitment to society April 21, 2020
Grifols continues to reinforce its commitment to all stakeholders as a response to COVID-19 April 21, 2020
Grifols and Shanghai RAAS close their strategic alliance in China March 27, 2020
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19 March 25, 2020
Grifols reinforces its commitment to all stakeholders as a response to the COVID-19 outbreak March 18, 2020
Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million February 27, 2020
Grifols and the Public Investment Fund of Saudi Arabia to boost plasma medicines self-supply in the region February 18, 2020
Grifols to launch TAVLESSE® in Europe and Turkey to continue reinforcing its commercial strategy and commitment to patients January 16, 2020

2019

Grifols launches XEMBIFY® 20% subcutaneous immunoglobulin, a new Primary Immunodeficiency treatment December 12, 2019

Click on this link to consult press releases prior to 2020.